Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 3, 1998, Pages 159-162

  Wong, Shekman L ^a   Drajesk, Jeffrey ^a   Chang, Min S ^a   Witt, Galen ^a   Awni, Walid M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

5 Lipoxygenase; Asthma; Pharmacokinetics

Indexed keywords

ATRELEUTON; LIPOXYGENASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; COLD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; LIVER DYSFUNCTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; VOLUNTEER;

ADULT; ARACHIDONATE 5-LIPOXYGENASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MALE; PLACEBOS;

EID: 0031899604     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199804)19:3<159::AID-BDD80>3.0.CO;2-O     Document Type: Article

References (7)

1. D.G. Batt, 5-Lipoxygenase inhibitors and their anti-inflammatory activities. Prog. Med. Chem., 29, 1-63 (1992).
2. R.A. Lewis, K.F. Austen and R.J. Soberman, Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human disease. New Engl. J. Med., 323, 645-655 (1990).
3. R.L. Bell, P.R. Young, D.H. Albert, C. Lanni, J.B. Summers, D.W. Brooks, P. Rubin and G.W. Carter, The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int. J. Immunopharmacol., 14, 505-510 (1992).
4. G.W. Carter, P.R. Young, D.H. Albert, J. Bouska, R. Dyer, R.L. Bel, J.B. Summers and D.W. Brooks, 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther., 256, 929-937 (1991).
5. K.P. Hui, I.K. Taylor, G.W. Taylor, P. Rubin, J. Kesterson, N.C. Barnes and P.J. Bames, Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax, 46, 184-189 (1991).
6. E. Israel, R. Dermarkarian, M. Rosenberg, R. Sperling, G. Taylor, P. Rubin and J.M. Drazen, The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. New Engl. J. Med., 323, 1740-1744 (1990).
7. E. Israel, P. Rubin, J.P. Kemp et al., The effects of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Inter. Med., 119, 1059-1066 (1993).